Leading swine veterinarians address overall vaccination compliance issues critical to effectively managing Mycoplasma hyopneumoniae and porcine circovirus in the latest At the Meeting (ATM) programme, produced by Dr Bob Morrison, University of Minnesota.
CHINA & GERMANY
Research driven pharmaceutical company Boehringer Ingelheim, in partnership with Taizhou China Medical City in Jiangsu Province, China, held a ground-breaking ceremony for a veterinary vaccine manufacturing plant at the China Medical City (Taizhou China Medicine High-Tech Development Zone) last week (Friday, 16 August).
US - Controlling swine diseases such as Porcine Reproductive and Respiratory Syndrome (PRRS), Porcine Circovirus Associated Disease (PCV2) and Mycoplasma pneumonia (M. hyo) is one of the the key challenges for producers and veterinarians. During the 2012 World Pork Expo, swine experts discussed the impacts of these diseases, the latest research and effective ways to manage respiratory diseases on modern production farms.
US - The research driven pharmaceutical company Boehringer Ingelheim will expand its global animal health vaccines business. With the completion of a series of major investments at the US site in St. Joseph, Missouri, the company will further enhance its position in the development and supply of vaccines against the most important diseases of pigs.
Strong, active piglets will stimulate the sow to produce the maximum amount of milk.
The EU Commission has approved the simultaneous use of the pig vaccines Ingelvac CircoFLEX® and Ingelvac MycoFLEX® in the European Union. Boehringer Ingelheim will market this unique vaccine concept under the name FLEXcombo®.
Get the latest news on Swine Health Subscribe to our newsletter